Anavex Life Sciences Corp (AVXL)

[tredenwater2]

The FDA ALWAYS in the history of Alz trials has always REQUIRED a ph 3 double blinded placebo controlled study. This is true (as others have pointed out) and was needed in determining how slow the progression of patients were in addition to side effects that were documented, some very nasty!

A 2-73 is unique in that it has chosen the adaptive approach with the power of 10(?) and has LITTLE TO NO SIDE EFFECTS ! Anecdotal evidence of super responders is accompanied with long term safety and possibly improving scores on a WHOL HOST OF TESTS by possibly all remaining patients (which last I checked was 72% ) still in the 2X extended trial.

A double blinded placebo is ALWAYS used until... it isn't needed. What if a drug like A 2-73 comes along and does exactly what we have seen and gets the perfect storm of events and gets approved with phase 3 or 4 confirmatory trials still in play. There is a FIRST time for EVERYTHING right? Is the data of the 25 that good that we are trying for BTD RIGHT NOW?

history in the making IMO!

Tred